Melanotan II (Lyophilized) 10mg - Peptides
The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII).The effects of melanotan-II, a non-specific agonist of melanocortin receptors, on erection and its possible sites of action were investigated in anesthetized rats. Erectile events were of higher amplitude in rats treated with melanotan-II i.t. (0.2 microg) delivered at the L6-S1 level than in animals treated with the vehicle i.t. delivered. Erectile responses elicited by cavernous nerve stimulation were increased after i.v. melanotan-II (1 mg/kg), thereby exerting facilitator effect on erection. These results lead to the conclusion that central and peripheral melanocortin pathways are recruited by melanotan-II, depending on its route of delivery, to exert both inducer and facilitator activities on erection. Melanotan II (MTII), can enhance sexual function in human males (erectile activity) and females (increased levels of sexual desire and genital arousal). Unlike other sexual-enhancement drugs, MTII works at the level of the brain, thus eliciting a rather natural sexual response with minimal or no undesirable side effects. The actions of the peptide were discovered accidentally while studying the effects of the peptide and related analogs on human skin pigmentation (tanning). Effective dosages were shown to be 0.02mg - 0.03mg per kilogram(2.2 pounds) of body weight. Adverse effects such as nausea, lethargy, and priapism were experienced by some who used a dosage higher than 0.03mg/kg. Effective cycle duration for tanning was shown to vary between skin types. Using the Fitzpatrick Skin Type Scale effective cycle length for type I, II, and III. No notable effects were shown for those with skin types IV or greater. Type I showed best results with a cycle duration of 15-18 subcutaneous injections, one per day, at desired concentration. Type II showed best results with a cycle duration of 12-15 subcutaneous injections, one per day, at target concentration. Finally, type III skin showed best results with a cycle duration of 9-12 subcutaneous injections, one per day, at target concentration. Melanotan II does degrade quickly at room temperature so unused powder should always be stored in the freezer and once constituted any unused portions need to be refrigerated and used fairly quickly there after.